How do I check that two SWB lots of orforglipron agree on content assay?

What I have: SWB · orforglipron.

Before I write this off, I want to check whether it is a known failure mode.

I have the lot number, the certificate and the date, and I am happy to compare them against anything.

What would you check first, and what would you conclude from each outcome?

If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

Assume segregation is possible, and design your sampling to catch it if it exists.

On the detail: the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

If testing multiple vials, state how many you tested and why you chose those vials.

Put another way, most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

edited 12 Apr 2025 by assay_blank — fixed an arithmetic slip in the third paragraph

Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

The relevant pharmacopoeial reference points here are the general chapters on peptide purity and on bacterial endotoxins; both specify method validation requirements that research-grade certificates almost never claim to meet, and the absence of that claim is itself information.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.